The Canadian Fabry Disease Initiative (CFDI) was a study that started in 2007 and concluded in early 2017. Through the CFDI, Fabry patients were provided with publicly funded access to either Health Canada-approved Fabrazyme (agalsidase beta) or Replagal (agalsidase alfa) on a randomized basis.

To date, the CFDI has released two follow-up studies written and published by Vancouver-based metabolic geneticist Dr. Sandra Sirrs and one of these studies can be read here.

Now that the study has concluded, CFDI has become the CFDI National Registry (CFDI-NR) which will continue to collect information on all persons with Fabry Disease in Canada who wish to enroll. Anyone in Canada who has been diagnosed with Fabry disease, or who may have Fabry disease based on a positive family history, is encouraged to ask their treating physician or family doctor about the CFDI-NR.

For more information, please visit the CFDI website here or call 1-877-998-9797.

For information on the treatment options available to Fabry patients in Canada, please speak with your physician. Funding for treatment will be dependent on your private health coverage or provincial/territorial public drug benefit program.